Category: FDA Drug Safety Oversight
-
Ortho Evra Update: October 2011 FDA Study Finds Increased Risk Of Blood Clot Side Effects Deep Vein Thrombosis & Pulmonary Embolism
Given These New FDA Drug Safety Findings About Ortho Evra, What Will Two Advisory Committees Do At Joint Meeting On December 9, 2011? (Posted by Tom Lamb at DrugInjuryWatch.com) On October 27, 2011 the FDA…
-
YAZ / Yasmin / Ocella Update: October 2011 FDA Study Finds Increased Risk Of Blood Clot Side Effects Like DVT, PE, Stroke, And Heart Attack
Safety Study Findings About Drospirenone (DRSP) Birth Control Pills Will Be On The Agenda For FDA Advisory Committees At Joint Meeting In December 2011 (Posted by Tom Lamb at DrugInjuryWatch.com) On October 27, 2011 the FDA…
-
NuvaRing Update: October 2011 FDA Study Finds Increased Risk Of Pulmonary Embolism (PE) And Deep Vein Thrombosis (DVT)
Will NuvaRing Safety Study Findings Be Addressed By FDA Advisory Committees At Joint Meeting In December 2011? (Posted by Tom Lamb at DrugInjuryWatch.com) ______________________________________________________________________________ UPDATE: "October 2013 NuvaRing Label Change: Warnings And Precautions Section…
-
Safety Of Ortho Evra Birth Control Patch Will Be Subject Of FDA Advisory Committees Meeting
Possibly Increased Risk Of Blood Clot-Related Side Effects Like PE And DVT Suggested By Postmarketing Studies (Posted by Tom Lamb at DrugInjuryWatch.com) _____________________________________________________________________ UPDATE: Ortho Evra: December 2011 FDA Advisory Committees Meeting Background Materials…
-
YAZ / Yasmin / Ocella: FDA Study Suggests An Increased Risk Of Blood Clots That Can Cause Side Effects Like Pulmonary Embolism
Early Results Suggest An Approximately 1.5-fold Increase In The Risk For Birth Control Pills With Drospirenone (DRSP) (Posted by Tom Lamb at DrugInjuryWatch.com) _____________________________________________________________________ UPDATE: YAZ / Yasmin / Ocella Update: October 2011 FDA…
-
European Medicines Agency (EMA) Recommends Multaq Use Should Be Restricted For Safety Reasons
EMA Cites The Increased Risks Of Liver Injury, Lung Side Effects, And Cardiovascular Adverse Events (Posted by Tom Lamb at DrugInjuryWatch.com) In late September 2011 the European Medicines Agency (EMA) recommended that the use…
-
Many Patients Mistakenly Believe That A Prescription Drug Must Be Safe If FDA-Approved
Safety Problems With New Medications Often Appear Only After Approval And Widespread Use (Posted by Tom Lamb at DrugInjuryWatch.com) A medical journal article published in the September 12, 2011 edition of the Archives of…
-
Public Citizen Group Files FDA Petition To Fix Problems Exposed By Mensing Case Ruling
Generic Drug Companies Should Have To Update Side Effect Warnings Or Face Drug Injury Lawsuits (Posted by Tom Lamb at DrugInjuryWatch.com) On August 29, 2011 the consumer advocacy group Public Citizen took action in…
-
Increased Risk Of Bladder Cancer Warning Added To Actos Label By Takeda Announced In August 2011
European Drug Regulator EMA Recommended New Actos Contra-Indications And Warnings In July 2011 (Posted by Tom Lamb at DrugInjuryWatch.com) _____________________________________________________________________ UPDATE: "European Medicines Agency clarifies opinion on pioglitazone and the risk of bladder cancer" …